Clinical characteristics | Cognitively impaired group (n = 24) | Cognitively unimpaired group (n = 16) | F-value | P-value |
Age | 63.79 ± 8.05 | 62.19 ± 9.51 | 0.404 | >0.05 |
Sex, % male | 83% | 76% | - | - |
Weight | 71.08 ± 6.05 | 69.50 ± 6.39 | 0.01 | >0.05 |
Levadopa dose mg/d | 531.67 ± 204.30 | 437.50 ± 230.03 | 0.35 | >0.05 |
duration of disease | 4.10 ± 1.37 | 2.71 ± 0.99 | 0.97 | <0.01 |
UPDRSIII score | 32 ± 2.78 | 21.31 ± 2.70 | 0.16 | <0.05 |
Hoehn & Yahr staging | 2.06 ± 0.71 | 1.84 ± 0.72 | 0.1 | >0.05 |
MMSE score | 20.08 ± 1.81 | 27.56 ± 1.59 | 0.43 | <0.001 |
MoCA score | 16.79 ± 1.79 | 25.19 ± 1.22 | 2.6 | <0.001 |
ADL score | 45.04 ± 6.10 | 50.13 ± 7.70 | 1.08 | <0.05 |